Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants
- PMID: 28682795
- DOI: 10.1097/MOG.0000000000000382
Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants
Abstract
Purpose of review: Pancreatic cancer, despite years of study and some progress, presents with a grim prognosis in almost all cases. In the current review, we have discussed recent studies that have attempted to decipher the genetic makeup of pancreatic ductal adenocarcinoma and preneoplastic pancreatic cystic neoplasms.
Recent findings: With the advent of high throughput sequencing, the genetic code of pancreatic cancer is beginning to unravel and this new-found information heralds an era of precision cancer care where treatment will be guided by the genetic code of the neoplasm. Results from these studies have pointed towards the complexity and heterogeneity of the pancreatic cancer genome, provided avenues to "tailor therapy" based as well as shed light on progression of preneoplastic pancreatic neoplasms into full blown invasive pancreatic ductal adenocarcinoma.
Summary: While this progress has made us closer to the model of precision medicine, significant obstacles need to be overcome to use this new-found information to change the way we manage patients with pancreatic cancer.
Similar articles
-
Genomics of pancreatic ductal adenocarcinoma.Hepatobiliary Pancreat Dis Int. 2014 Aug;13(4):381-5. doi: 10.1016/s1499-3872(14)60281-2. Hepatobiliary Pancreat Dis Int. 2014. PMID: 25100122 Review.
-
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.Gastroenterology. 2016 Jan;150(1):48-63. doi: 10.1053/j.gastro.2015.08.056. Epub 2015 Sep 15. Gastroenterology. 2016. PMID: 26385075 Free PMC article. Review.
-
The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go.Mod Pathol. 2020 Dec;33(12):2544-2563. doi: 10.1038/s41379-020-0629-6. Epub 2020 Jul 23. Mod Pathol. 2020. PMID: 32704031 Free PMC article. Review.
-
Can we move towards personalised pancreatic cancer therapy?Expert Rev Gastroenterol Hepatol. 2014 May;8(4):335-8. doi: 10.1586/17474124.2014.893820. Epub 2014 Apr 4. Expert Rev Gastroenterol Hepatol. 2014. PMID: 24702631 No abstract available.
-
Genetics of Familial and Sporadic Pancreatic Cancer.Gastroenterology. 2019 May;156(7):2041-2055. doi: 10.1053/j.gastro.2018.12.039. Epub 2019 Jan 18. Gastroenterology. 2019. PMID: 30660730 Review.
Cited by
-
AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.PLoS One. 2023 Nov 9;18(11):e0294065. doi: 10.1371/journal.pone.0294065. eCollection 2023. PLoS One. 2023. PMID: 37943821 Free PMC article.
-
SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment.Front Oncol. 2022 Jun 16;12:890154. doi: 10.3389/fonc.2022.890154. eCollection 2022. Front Oncol. 2022. PMID: 35785187 Free PMC article.
-
Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments.Front Oncol. 2024 Jul 1;14:1386699. doi: 10.3389/fonc.2024.1386699. eCollection 2024. Front Oncol. 2024. PMID: 39011469 Free PMC article. Review.
-
Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with fibrosis.Cancer Biomark. 2023;38(3):287-300. doi: 10.3233/CBM-220044. Cancer Biomark. 2023. PMID: 37955079 Free PMC article.
-
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458. Epub 2023 Nov 21. Eur J Cancer. 2024. PMID: 38039779 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials